Vanguard Capital Management
ZBIO

Vanguard Capital Management’s Zenas BioPharma ZBIO Stock Holding History

Vanguard Capital Management’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.4M Buy
1,354,864
+109,473
+9% +$2.18M ﹤0.01% 2139
2026
Q1 		$24.3M Buy
+1,245,391
New +$28M ﹤0.01% 2232

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management's ZBIO Position: Q2 2026 in Review

Vanguard Capital Management increased its Zenas BioPharma (ZBIO) stake by 8.8% in Q2 2026, buying an estimated $2.18M and bringing the position to 1,354,864 shares worth $34.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2139.

Vanguard Capital Management first reported a position in ZBIO in Q1 2026 and has held it in 2 quarters since. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • Vanguard Capital Management held 1,354,864 shares of Zenas BioPharma worth $34.4M as of Q2 2026.
  • Vanguard Capital Management bought 109,473 Zenas BioPharma shares in Q2 2026, an estimated $2.18M.
  • Zenas BioPharma made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2139 holding.
  • Vanguard Capital Management first reported a position in Zenas BioPharma in Q1 2026 and has held it in 2 quarters since.
  • 144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.